Immune Therapeutics

About:

Immune Therapeutics benefits patients with chronic diseases by rebalancing their bodies' immune system by using a patented immunotherapy.

Website: http://immunetherapeutics.com/

Twitter/X: TNIBiotech

Description:

At Immune Therapeutics (formerly known as TNI BioTech, Inc.), their goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy. Their products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapy. Immune Therapeutics' most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low-dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to the activation and expansion of various cells in the immune system.

Total Funding Amount:

$2.89M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Bethesda, Maryland, United States

Founded Date:

1993-12-02

Contact Email:

facebook(AT)immunetherapeutics.com

Founders:

Noreen Griffin

Number of Employees:

11-50

Last Funding Date:

2013-09-25

IPO Status:

Public

Industries:

© 2025 bioDAO.ai